Literature DB >> 28388401

PARP Inhibitors for Cancer Therapy.

Ken Y Lin1, W Lee Kraus2.   

Abstract

Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28388401     DOI： 10.1016/j.cell.2017.03.034

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  33 in total

Review 1.  Preserving genome integrity and function: the DNA damage response and histone modifications.

Authors:  Jae Jin Kim; Seo Yun Lee; Kyle M Miller
Journal:  Crit Rev Biochem Mol Biol       Date:  2019-06-04       Impact factor: 8.250

2.  Nicotinamide Pathway-Dependent Sirt1 Activation Restores Calcium Homeostasis to Achieve Neuroprotection in Spinocerebellar Ataxia Type 7.

Authors:  Colleen A Stoyas; David D Bushart; Pawel M Switonski; Jacqueline M Ward; Akshay Alaghatta; Mi-Bo Tang; Chenchen Niu; Mandheer Wadhwa; Haoran Huang; Alex Savchenko; Karim Gariani; Fang Xie; Joseph R Delaney; Terry Gaasterland; Johan Auwerx; Vikram G Shakkottai; Albert R La Spada
Journal:  Neuron       Date:  2019-12-16       Impact factor: 17.173

3.  Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome.

Authors:  David Lemchak; Swati Banerjee; Shaunak S Digambar; Brian L Hood; Thomas P Conrads; Jaroslaw Jedrych; Larisa Geskin; Oleg E Akilov
Journal:  Exp Dermatol       Date:  2017-12-21       Impact factor: 3.960

Review 4.  Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.

Authors:  Triparna Sen; Carl M Gay; Lauren Averett Byers
Journal:  Transl Lung Cancer Res       Date:  2018-02

Review 5.  Histone methylation and the DNA damage response.

Authors:  Fade Gong; Kyle M Miller
Journal:  Mutat Res Rev Mutat Res       Date:  2017-09-23       Impact factor: 5.657

6.  AI26 inhibits the ADP-ribosylhydrolase ARH3 and suppresses DNA damage repair.

Authors:  Xiuhua Liu; Rong Xie; Lily L Yu; Shih-Hsun Chen; Xiaoyun Yang; Anup K Singh; Hongzhi Li; Chen Wu; Xiaochun Yu
Journal:  J Biol Chem       Date:  2020-08-04       Impact factor: 5.157

Review 7.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 8.  Poly(ADP-ribose): A Dynamic Trigger for Biomolecular Condensate Formation.

Authors:  Anthony K L Leung
Journal:  Trends Cell Biol       Date:  2020-02-20       Impact factor: 20.808

9.  Androgen signaling uses a writer and a reader of ADP-ribosylation to regulate protein complex assembly.

Authors:  Chun-Song Yang; Kasey Jividen; Teddy Kamata; Natalia Dworak; Luke Oostdyk; Bartlomiej Remlein; Yasin Pourfarjam; In-Kwon Kim; Kang-Ping Du; Tarek Abbas; Nicholas E Sherman; David Wotton; Bryce M Paschal
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 17.694

Review 10.  PARP inhibitors in gastric cancer: beacon of hope.

Authors:  Yali Wang; Kun Zheng; Yongbiao Huang; Hua Xiong; Jinfang Su; Rui Chen; Yanmei Zou
Journal:  J Exp Clin Cancer Res       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.